@article{cac3110692f94626ab58619b809e9b55,
title = "Psychometric evaluation and adaptation of the Spine Oncology Study Group Outcomes Questionnaire to evaluate health-related quality of life in patients with spinal metastases",
abstract = "BACKGROUND: The Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ) was developed as the first spine oncology-specific health-related quality of life (HRQOL) measure. This study evaluated the psychometric properties and clinical validity of the SOSGOQ in a diverse cohort of patients with spinal metastases. METHODS: An international, multicenter, prospective observational cohort study including patients with spinal metastases who underwent surgery and/or radiotherapy was conducted by the AOSpine Knowledge Forum Tumor. Demographic, tumor, and treatment data were collected. HRQOL was evaluated using the SOSGOQ and Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) at baseline and fixed follow-up times. Construct validity was assessed using multitrait scaling analyses, confirmatory factor analyses, and correlation with the SF-36 and NRS pain score. Test-retest reliability was assessed in a subgroup of patients between 12 weeks after treatment and the retest 4 to 9 days later. RESULTS: A total of 238 patients were enrolled at 9 centers across North America; 153 of these patients had HRQOL data available at 12 weeks after treatment. Multitrait scaling analyses and confirmatory factor analyses resulted in a refined version of the SOSGOQ with 4 domains and 4 single items. The revised SOSGOQ (SOSGOQ2.0) demonstrated strong correlations with SF-36 and the ability to discriminate between clinically distinct patient groups. Reliability of the SOSGOQ2.0 was demonstrated to be good, with an intraclass correlation coefficient ranging from 0.58 to 0.92 for the different domains. CONCLUSIONS: The SOSGOQ2.0 is a reliable and valid measure with which to evaluate HRQOL in patients with spinal metastases. It is recommended to use the SOSGOQ2.0 together with a generic HRQOL outcome measure to comprehensively assess HRQOL and increase sensitivity and specificity. Cancer 2018;124:1828-38.",
keywords = "metastases, patient-reported outcomes, quality of life, reliability, spine, validity",
author = "{AOSpine Knowledge Forum Tumor} and Versteeg, {Anne L.} and Arjun Sahgal and Rhines, {Laurence D.} and Sciubba, {Daniel M.} and Schuster, {James M.} and Weber, {Michael H.} and Varga, {Peter Pal} and Stefano Boriani and Chetan Bettegowda and Fehlings, {Michael G.} and Clarke, {Michelle J.} and Arnold, {Paul M.} and Gokaslan, {Ziya L.} and Fisher, {Charles G.}",
note = "Funding Information: This study was organized and funded by AOSpine International through the AOSpine Knowledge Forum Tumor, a pathology-focused working group of up to 10 international spine experts acting on behalf of AOSpine in the domain of scientific expertise. A research grant for this study was received from the Orthopaedic Research and Education Foundation. Funding Information: Anne L. Versteeg has received personal fees from AOSpine International for work performed outside of the current study. Arjun Sahgal has received personal fees for past educational seminars from Elekta AB, Accuray Inc, and Varian Medical Systems; has received a research grant from Elekta AB; and has received fees for travel accommodations/expenses from Elekta and Varian Medical Systems for work performed outside of the current study. Dr. Sahgal also belongs to the Elekta MR-Linac Research Consortium. Laurence D. Rhines has received educational grants from Stryker and Medtronic for work performed outside of the current study. Daniel M. Sciubba has received personal fees from Medtronic, DePuy-Synthes, Stryker, NuVasive, and K2M for work performed outside of the current study. Paul M. Arnold has received fees for sponsored or reimbursed travel from AOSpine North America; has received personal fees from Spine Wave; has intellectual property rights and interests in, equity, or a position of responsibility with Evoke Medical; has equity with Z-Plasty; has received personal fees from Stryker Orthopaedics and Medtronic Sofamor Danek USA; has received personal fees and travel expenses from Stryker Spine and Medtronic; and has received personal fees from In Vivo, In Vivo Therapeutics, SpineGuard, and Ulrich for work performed outside of the current study. Ziya L. Gokaslan has received research support from AOSpine North America and is a stockholder in Spinal Kinetics for work performed outside of the current study. Charles G. Fisher has received personal fees from Medtronic and NuVasive, has received a grant to his institution from the Orthopaedic Research and Education Foundation (which was transferred from Dr. Fisher to AOSpine Knowledge Forum Tumor), and has received fellowship support to his institution from AOSpine and Medtronic for work performed outside of the current study. This study was organized and funded by AOSpine International through the AOSpine Knowledge Forum Tumor, a pathology-focused working group of up to 10 international spine experts acting on behalf of AOSpine in the domain of scientific expertise. A research grant for this study was received from the Orthopaedic Research and Education Foundation. Funding Information: Anne L. Versteeg has received personal fees from AOSpine International for work performed outside of the current study. Arjun Sah-gal has received personal fees for past educational seminars from Elekta AB, Accuray Inc, and Varian Medical Systems; has received a research grant from Elekta AB; and has received fees for travel accommodations/expenses from Elekta and Varian Medical Systems for work performed outside of the current study. Dr. Sahgal also belongs to the Elekta MR-Linac Research Consortium. Laurence D. Rhines has received educational grants from Stryker and Medtronic for work performed outside of the current study. Daniel M. Sciubba has received personal fees from Medtronic, DePuy-Synthes, Stryker, NuVasive, and K2M for work performed outside of the current study. Paul M. Arnold has received fees for sponsored or reimbursed travel from AOSpine North America; has received personal fees from Spine Wave; has intellectual property rights and interests in, equity, or a position of responsibility with Evoke Medical; has equity with Z-Plasty; has received personal fees from Stryker Orthopaedics and Medtronic Sofamor Danek USA; has received personal fees and travel expenses from Stryker Spine and Med-tronic; and has received personal fees from In Vivo, In Vivo Therapeutics, SpineGuard, and Ulrich for work performed outside of the current study. Ziya L. Gokaslan has received research support from AOSpine North America and is a stockholder in Spinal Kinetics for work performed outside of the current study. Charles G. Fisher has received personal fees from Medtronic and NuVasive, has received a grant to his institution from the Orthopaedic Research and Education Foundation (which was transferred from Dr. Fisher to AOSpine Knowledge Forum Tumor), and has received fellowship support to his institution from AOSpine and Medtronic for work performed outside of the current study. Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society",
year = "2018",
month = apr,
day = "15",
doi = "10.1002/cncr.31240",
language = "English (US)",
volume = "124",
pages = "1828--1838",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",
}